Health
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE – PharmiWeb.com
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE…
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
- This is the first authorisation to be issued by the MHRA under Project Orbis.1
- AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
- Patients with early-stage lung cancer are treated…
Continue Reading
-
Noosa News23 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General19 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General16 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
Noosa News20 hours agoLocal nurse Carra Luke identified as woman found dead from critical injuries in Brisbane